Vaccinex Announces Three Oral Presentations Highlighting Semaphorin 4D (SEMA4D) at the ASCO-SITC Clinical Immuno-Oncology Symposium

NEXT STORY
Generex Biotechnology Subsidiaries NuGenerex Immuno-Oncology and NuGenerex Diagnostics Working to Address the Coronavirus Pandemic and Emerging Risk of Avian Flu Using Ii-Key Peptide Vaccines
PREV STORY
Vaccines Industry Insights 2020; Forecast to 2024 – Leading Players are GlaxoSmithKline, Pfizer, Sanofi Pasteur and Merck
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Progenics Pharmaceuticals Announces FDA Approval for AZEDRA® (iobenguane I 131) to Treat Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma

The First FDA-Approved Treatment for These Rare, Life-Threatening Neuroendocrine Cancers in Patients Aged 12 and ...

author_avatar
NASDAQ Market News

Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market is projected to reach US$56,737.2 Million in 2031: Visiongain Research Inc

author_avatar
NASDAQ Market News

CorMedix Inc. to Present at the Jefferies Virtual Healthcare Conference

author_avatar
NASDAQ Market News